🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Stopped by my favorite booth at the ASCO exhibition MD Anderson Cancer Center and caught up with dear friends @naborala Omar Alhalabi, MD #ASCO24 #Networking #Oncology

One of today's top presentations by G Curigliano MD PhD on predictors of response and toxicity in ADCs. #ASCO24 #Oncology #CancerResearch OncoAlert OncoDaily

Good morning! Heading out early to explore the DB-06 data! Excited to dive into the details! #ASCO24 OncoAlert

DB-06 #ASCO24: - significant improvement in PFS with TDX-D vs TPC in HR+HER2 low mBC post-CDK4/6i - similar result in ultra-low HER2 -OS data is immature - ILD any grade 11.3% in TDX-D arm. 🚦TDX-d should be used post ET + It works for ultra-low HER2 OncoAlert G Curigliano MD PhD

Congratulations Aydah AlAwadhi, MD 🇦🇪 #ASCO24 poster presentation #UAE #MedicalEducation #OncologyMentors Emirates Oncology Society

تمكين المرأة الإماراتية.. استراتيجيّة تبرز نماذج مضيئة في المجتمع kulalusra.ae/talks/spotligh…

A State of Art lecture by Prof. William Kaelin on What Makes a Good Cancer Target Key lessons: •Correlation ≠ causation. •Poor prognostic biomarkers are not always good targets. •Creative trial designs are essential moving forwards. #SABCS2024 #SABCS24 SABCS #bcsm

ترقبوا الحلقة الـ134 من "دكتور برق" بعنوان: "الوردي لا ينتهي في أكتوبر" ضيفة الحلقة: الدكتورة عايدة محمد العوضي استشاري طب الأورام هذه الحلقة مقدمة برعاية "نوفارتس" 🗓️ الإثنين 6 يناير 2025 🕘 9 مساءً بتوقيت الإمارات بث مباشر على: #برق_الإمارات Dr Ameera Al Khaja Novartis

us02web.zoom.us/webinar/regist…

What’s a life-saving medical fact everyone should know?

من رحلة قريبة، لفت انتباهي شكل هذه الشجرة وكأنه يجسّد اسم الخالق .. سبحان الله 🙏🏻

"افخَر بنفسك بصمت، فأنت وحدك تدرك كم من الليالي سهرت، وكم من الأبواب طرقت، وكم من العقبات تجاوزت لتصل إلى ما أنت عليه اليوم... مجدك قصة لا يفهمها سواك". #الدكتورة_أميمة_القاسمي #ProfOmaimaAlqasimi #إستاذة_أكاديمية #Academic_Professor

VERITEC-2: Vepdegestrant, the first PROTAC ER degrader to show a significant PFS benefit over fulvestrant in ESR1m ER+/HER2- MBC. Favorable safety profile with few AEs (<5%) requiring dose changes. OS still maturing. A potential new option in the ER-resistant space. #ASCO25

INAVO120: Inavolisib shows significant OS benefit in PIK3CA-mutant HR+/HER2- MBC. 🧬 Median OS: 34.0 vs 27.0 months 📉 HR: 0.67 (p=0.019) ✅ 7-month survival gain with longer follow-up (34.2 mo) Much longer time to chemotherapy #BreastCancer OncoAlert #ASCO25

#ASCO25: OPTIMAL Trial DHP107 (oral paclitaxel) vs IV paclitaxel PFS non-inferior: 10.0 vs 8.5 mo (HR 0.87) OS, ORR, DCR, QoL comparable Fewer peripheral neuropathy & hypersensitivity events Oral option offers convenience with manageable safety OncoAlert

#ASCO25 : DESTINY-Breast06 💥 T-DXd showed superior PFS vs TPC in HR+/HER2-low or ultra-low mBC 🧬 Benefit consistent across subgroups: 🔹 PI3K/AKT: HR 0.61–0.65 🔹 ESR1: HR 0.59–0.64 🔹 BRCA1/2: HR 0.14–0.69 📈 ORR & PFS2 also favored T-DXd ✅ Efficacy regardless of mutation

ABCSG 45: #ASCO25 🔬 In HRD+ TNBC: ➡️ ~50% have intra-tumoral BRCA1/2 PV ➡️ BRCA1/2 PV: Carbo/Olaparib led to >77% RCB 0/I ➡️ BRCA1/2 WT: Limited Carbo/Ola benefit; TAC remains effective OncoAlert

NeoSTAR Trial: #ASCO25 🚨 1st study of SG (Sacituzumab Govitecan) + P (Pembrolizumab) in early TNBC ✅ 32% pCR after 4 cycles SG/P ✅ 50% pCR with SG/P ± chemo (non-anthracycline) 🛡️ Safe: Low discontinuation (10%), few dose reductions 📌 Ongoing biomarker work to guide response